Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Another Epigenetics Agreement Signed
by Patricia L. Short
April 27, 2009
| A version of this story appeared in
Volume 87, Issue 17
U .K.-based biotech company CellCentric has added two university professors—Ramin Shiekhattar and Luciano Di Croce, both of Barcelona's Center for Genomic Regulation—to its research network. The deal gives CellCentric 25 such agreements with labs around the world. CellCentric says it is building a portfolio of epigenetic-related technologies, including screens and markers. It also has six small-molecule discovery programs under way. Epigenetics is an emerging field investigating the processes that help govern chromatin structure and function, by which cell fate is controlled (C&EN, April 6, page 28).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X